

John Paul Seenan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3125107/publications.pdf>

Version: 2024-02-01

13
papers

91
citations

1684188

5
h-index

2053705

5
g-index

13
all docs

13
docs citations

13
times ranked

140
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease – new insights into dietary disease triggers. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 935-947.	3.7	49
2	Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2067-2075.	2.8	17
3	Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease. <i>Nutrients</i> , 2021, 13, 2899.	4.1	11
4	Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2021, 12, 345-347.	1.8	8
5	Acute interstitial nephritis secondary to vedolizumab. <i>BMJ Case Reports</i> , 2021, 14, e243568.	0.5	5
6	PTH-133 – Therapeutic drug monitoring supports clinical decision making when employed before and after biosimilar infliximab switching. , 2019, , .		1
7	PTH-132 – High rates of clinical response are maintained after switching from originator to biosimilar infliximab. , 2019, , .		0
8	P153 – Low rates of subtherapeutic drug levels are observed with proactive therapeutic drug monitoring of infliximab. , 2021, , .		0
9	P154 – Vedolizumab drug levels are not associated with outcomes or disease activity in inflammatory bowel disease. , 2021, , .		0
10	P150 – Adalimumab therapeutic drug monitoring – “ does time of testing matter?. , 2021, , .		0
11	P152 – Low rates of subtherapeutic drug levels are observed with proactive therapeutic drug monitoring of adalimumab. , 2021, , .		0
12	P275 – Analysis of exclusive enteral nutrition formulas in Crohn's disease – new insights into dietary triggers. , 2021, , .		0
13	PMO-21 – Impact of COVID-19 on infliximab prescribing practices in inflammatory bowel disease. , 2021, , .		0